Pharmaceuticals

Acute Intermittent Porphyria Market Trends And Growth Outlook Across The 2026–2030 Forecast Period

May 18, 2026May 18, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

By 2030, How Much Growth In Market Size Is Expected For The Acute Intermittent Porphyria Market?

The acute intermittent porphyria market has experienced significant expansion in recent years. It is projected to grow from $4.66 billion in 2025 to $4.97 billion in 2026, at a compound annual growth rate (CAGR) of 6.5%. This historical growth can be attributed to several factors including the limited availability of diagnostic facilities for AIP, low awareness regarding acute intermittent porphyria, a reliance on traditional treatment methods, the increasing hospital and clinic infrastructure, and the growing demand for genetic testing.

The acute intermittent porphyria market size is projected to experience robust expansion in the coming years. Its valuation is set to reach $6.33 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.2%. This anticipated growth throughout the forecast period stems from factors such as the creation of new therapies and hematin formulations, the broadening of DNA and enzyme testing services, greater incorporation of telemedicine for rare conditions, increased awareness and educational initiatives for medical professionals, and the implementation of advanced monitoring and digital health instruments. Key developments anticipated during this timeframe involve a higher uptake of genetic and enzyme-based diagnostic methods, heightened understanding regarding the timely diagnosis and treatment of AIP, an increase in prophylactic hematin infusions and targeted therapeutic approaches, the proliferation of specialized treatment facilities and research initiatives, and the incorporation of telemedicine alongside remote patient monitoring for individuals with AIP.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19264&type=smp

Which Strategic Drivers Are Supporting The Acute Intermittent Porphyria Market Development?

The increasing occurrence of metabolic disorders is anticipated to fuel the expansion of the acute intermittent porphyria market in the future. These disorders encompass various conditions stemming from atypical chemical reactions within the body, which interfere with normal metabolic processes. Their widespread occurrence is attributable to genetic predispositions, lifestyle choices, environmental impacts, and enhanced diagnostic capabilities and public awareness. This increase in metabolic disorders prompts the pharmaceutical sector to allocate resources towards developing therapies for uncommon genetic conditions like acute intermittent porphyria. For example, data from December 2023, provided by Cleveland Clinic, a US-based nonprofit academic medical center, indicates that inherited metabolic disorders collectively affect about 1 in 1,000 to 2,500 births worldwide. Consequently, the widespread presence of metabolic disorders is a key factor propelling the expansion of the acute intermittent porphyria market.

What Segment Types Are Included In The Acute Intermittent Porphyria Market Analysis?

The acute intermittent porphyria market covered in this report is segmented –

1) By Diagnosis: Urine Test, Blood Test, Serum Test, DNA Test, Other Diagnosis

2) By Treatment: Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, Other Treatments

3) By End-Users: Hospitals And Clinics, Ambulatory Surgical Centers, Research Centers

Subsegments:

1) By Urine Test: Urine Porphobilinogen (PBG) Test, Urine Aminolevulinic Acid (ALA) Test, Urine Color Change Test

2) By Blood Test: Plasma Porphyrin Levels Test, Blood Aminolevulinic Acid (ALA) Test, Complete Blood Count (CBC) Test

3) By Serum Test: Serum Porphyrin Levels Test, Liver Function Test (LFT), Serum ALA and PBG Enzyme Test

4) By DNA Test: Genetic Mutation Testing, Gene Sequencing Test

5) By Other Diagnosis: Stool Test for Porphyrins, Imaging Tests (CT/MRI Scans for Complications), Enzyme Activity Assays.

Which Trends Are Contributing To Changes In The Acute Intermittent Porphyria Market?

Major companies operating in the acute intermittent porphyria market are prioritizing the development of innovative products, such as acute intermittent porphyria management tablets, to better serve customers with enhanced features. Acute intermittent porphyria management tablets refer to oral medications utilized to manage or prevent the symptoms and acute attacks associated with AIP. For instance, in October 2023, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical company, announced the US Food & Drug Administration (USFDA) approval for its Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg. Chlorpromazine hydrochloride tablets USP, available in doses of 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, are employed to manage the symptoms of psychotic disorders and treat schizophrenia. They also help control nausea and vomiting, alleviate restlessness and apprehension before surgery, and act as an adjunct in treating tetanus. Additionally, these tablets are used in the management of acute intermittent porphyria, to control manic symptoms of manic-depressive illness, and to provide relief from intractable hiccups.

Which Companies Are Engaged In The Acute Intermittent Porphyria Market Environment?

Major companies operating in the acute intermittent porphyria market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., Mylan N.V., Clinuvel Pharmaceuticals Ltd., Recordati Rare Diseases Inc.

Access The Complete Acute Intermittent Porphyria Market Report:

https://www.thebusinessresearchcompany.com/report/acute-intermittent-porphyria-global-market-report

Which Geographic Region Represents The Largest Acute Intermittent Porphyria Market Share?

North America was the largest region in the acute intermittent porphyria market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute intermittent porphyria market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Acute Intermittent Porphyria Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=19264&type=smp

Browse Through More Reports Similar to the Global Acute Intermittent Porphyria Market 2026, By The Business Research Company

Acute Myeloid Leukemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report

Acute Ischemic Stroke Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report

Post Acute Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/post-acute-care-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795